Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study builds on a rapid-response CSF ctDNA approach to diagnose PCNSL and track how patients respond to treatment. It includes adults with pathologically confirmed PCNSL whose disease is confined to the CNS, and it uses HD-MTX-based chemotherapy with a BTK inhibitor as part of treatment. The goal is to see if CSF ctDNA patterns correlate with diagnostic results and treatment response, potentially enabling faster decisions in clinical practice. The study leverages an emergency-to-pathology workflow and prior evidence of ctDNA’s diagnostic and monitoring value in PCNSL. Data are collected under careful follow-up to evaluate feasibility and associations with outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pathologically confirmed primary central nervous system lymphoma;
* Lesions confined to the central nervous system (cerebral parenchyma, meninges, spinal cord or intraocular), with no evidence of systemic lymphoma;
* Aged ≥ 18 years and ≤ 75 years, no restriction on gender;
* Expected survival of more than 3 months;
* The subjects voluntarily join this study, understand the trial procedures and contents, sign the informed consent form, have good compliance and cooperate with follow-up.

Exclusion Criteria:

* Other types of central nervous system tumors;
* Without pathological confirmation basis;
* Patients complicated with other malignant tumors;
* Other conditions that are considered by the investigators to be unsuitable for participating in this trial.

Where it's running

• Deparment of neurosurgery, Beijing tiantan hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Xiaohui Ren — Department of Neurosurgery, Beijing Tiantan Hospital
• Study coordinator: Xiaohui Ren, MD
• Email: xiaohuiren@mail.ccmu.edu.cn/xiaohuiren@aliyun.com
• Phone: +86-010-59975567

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Tirabrutinib maintenance therapy for patients with primary CNS lymphoma in remission

  This study is testing if taking tirabrutinib every day can help people with primary CNS lymphoma stay in remission longer after their initial treatment.

  Recruiting Phase 2 Kyorin University · Tokyo · NCT06940791

• Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma

  This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06922604

• Using RMTT regimen as first-line therapy for primary central nervous system lymphoma

  This study is testing if a new combination treatment called RMTT can help people with primary central nervous system lymphoma who haven't had treatment before.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06832267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.